Search for in
Fentanyl patches
To add to the choice of opioid analgesics used in palliative care we now have in Australia fentanyl patches. Each patch is worn for 72 hours and has about the same effect as using twice daily oral sustained release(SR) morphine. However from a quality of life point of view there are some advantages in using fentanyl patches for some patients. It is not yet listed on the Pharmaceutical Benefits Scheme and is quite expensive. So what is its present role in palliative care and how is it used?

The main side effects complained of by patients on morphine are nausea, vomiting, constipation and drowsiness all of which can significantly impact on quality of life even though pain relief may be adequate. For total pain management both physical and psychological factors need to be taken into account. According to a study comparing transdermal fentanyl versus sustained release oral morphine the following has been found.20(1)

Pain control


No significant difference was found between fentanyl and SR morphine in regards to pain control. However those on fentanyl did require slightly more breakthrough doses of morphine.

Sedation and sleep


Fentanyl appeared to be less sedating than morphine both in the daytime and night.

Bowel function


Fentanyl treatment was associated with significantly less constipation than morphine.

Nausea


This was significantly lower in the fentanyl group.

Treatment preferences


Significantly more patients indicated that the fentanyl patches had caused less interruption to their daily activities and the activities of family and carers, and had been more convenient to take than morphine tablets.

Side effects


Skin - 3% erythema, 5% mild itching and 2% moderate itching.

Transferring from morphine to fentanyl


Withdrawl from morphine symptoms were common and symptoms such as abdominal pain, agitation or anxiety, sweating and 'flu' like symptoms were reported during the first few days of fentanyl treatment consistent with morphine withdrawl.

A second line drug


It should be emphasised that fentanyl is not suitable for unstable pain or rapid titration. In those situations morphine must first be used preferably on a four hourly basis until adequate pain control is acheived. If there are then indications to use fentanyl then the change is made according to the conversion formula listed below.

24-hour morphine (mgm/day) Fentanyl dose (mcg/hr)
<135 25
135-224 50
225-314 75
315-404 100
405-494 125
495-584 150
585-674 175
675-764 200
765-854 225
855-944 250
945-1034 275
1035-1124 300


There are four sizes of patch and more than one patch can be used if a higher dose is needed.The four sizes of patch have a delivery rate of 25,50,75 and 100mcg per hour.

Notes


(1) Fentanyl is excreted in the urine and the dose may need to be reduced if there is increasing dehydration or renal failure.
(2) As regards cost fentanyl is approximately three times as expensive as morphine.
(3) Care must be taken to adequately dispose of used patches and it is recommended that sharps containers be used for disposal.

Summary


Fentanyl is a very good opioid analgesic that is particularly useful for those people who are intolerant of morphine. However it should be considered a second line drug after morphine and is not nearly as flexible as 4 hourly morphine. It is used particularly for those with severe morphine related constipation or nausea, those who have excessive morphine induced sedation, those with poor compliance or inability to swallow and those who have inadequate pain relief with morphine. It is easy to use and well accepted by the patient. It will hopefully soon be listed on the PBS.


(1) Reference: Transdermal Fentanyl versus Sustained-Release Oral Morphine in Cancer Pain: Preference, Efficacy and Quality of Life. Journal of Pain and Symptom Management. Vol 13, No.5, May 1997.

See also Fentanyl Patches - Update

Top of Page

 Previous Index 1
Fentanyl patches - update
Palliative Care
Index
 Next
Euthanasia – the morning tea version
© 2007 Northern Rivers General Practice Network
16 Carrington Street (PO Box 519), Lismore, NSW 2480, Australia.
Ph: +61 (0)2 6622 4453 Fax: +61 (0)2 6622 3185
Email: Webmaster Email: Feedback
Disclaimer and Privacy Statement